Islet autoantibody seroconversion in the DPT-1 study: justification for repeat screening throughout childhood

Area of Science:

• Endocrinology
• Immunology
• Pediatrics

Background:

• Type 1 diabetes autoimmunity often starts in childhood, but the precise relationship between age and disease development is not fully understood.
• Identifying the optimal age for screening and intervention is crucial for managing type 1 diabetes.

Purpose of the Study:

• To investigate the age-specific timing of seroconversion to diabetes-associated autoantibodies (DAAs).
• To assess the risk of developing DAAs in relatives of type 1 diabetes patients based on age.

Main Methods:

• Utilized data from the Diabetes Prevention Trial-Type 1 (DPT-1) involving screening of 42,447 children aged 3-18 for DAAs.
• Followed up with 11,813 antibody-negative subjects for rescreening to determine seroconversion rates.

Main Results:

• Autoantibody seroconversion occurred in 4% of children, with a median time to seroconversion of 2 years.
• The risk of seroconversion to DAAs was highest in early childhood, decreasing by 5% for each year of increased age.
• The majority of children (75%) seroconverted by age 13.

Conclusions:

• Autoantibody seroconversion in type 1 diabetes is significantly age-dependent, with younger children exhibiting the highest risk.
• Early childhood screening for DAAs is recommended to identify individuals at high risk for type 1 diabetes.
• Initiating annual screenings from early childhood through adolescence can help identify the majority of subjects eligible for type 1 diabetes prevention trials.